Applicant: Robert Sackstein Attorney's Docket No.: 10286-014001 / BWH-729

Serial No.: 10/042,421
Filed: October 18, 2001

Page : 2 of 22

Amendment to the Title:

Please replace the title with the following amended title:

HEMATOPOIETIC CELL E-SELECTION/L-SELECTIN LIGAND POLYPEPTIDES

AND METHODS OF USE THEREOF

Amendments to the Specification:

Please replace the paragraph beginning at page 10, line 21 with the following amended paragraph:

Preferably the CD44 polypeptide is the standard or hematopoietic isoform of CD44 (CD44H). Alternately, the CD44 polypeptide is the R1 (CD44R1) or R2 isoform (CD44R2). For example, a HCELL polypeptide comprises the amino acid sequence of SEQ ID NO:1. (Gen Bank® Acc. CAA40133; Table 1) A HCELL polypeptide is at least about 30%, 50%, 70%, 80%, or 95% identical to the polypeptide sequence of SEQ ID NO:1.

Please replace the paragraph beginning at page 27, line 7 with the following amended paragraph:

Suitable sources of nucleic acids encoding CD44 polypeptide include for example the human CD44 nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. LO5407 and CAA40133, respectively. Other sources include human CD44 nucleic acid and protein sequences are shown in GenBank® Accession No. U35632 and P16079, respectively, and are incorporated herein by reference in their entirety. Suitable sources of nucleic acids encoding glycosyltransferase polypeptide include for example the human glycosyltransferase nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. AJ276689 and CAB81779, respectively. Suitable sources of nucleic acids encoding glycosidase polypeptide include for example the human glycosidase nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. AJ278964 and

Applicant: Robert Sackstein Attorney's Docket No.: 10286-014001 / BWH-729

Serial No.: 10/042,421
Filed: October 18, 2001

Page : 3 of 22

CAC08178, respectively. The use of other CD44, glycosyltransferase, or glycosidase polypeptides and nucleic acids know in the art are also within the scope of the invention.

Please replace the paragraph beginning at page 29, line 11 with the following amended paragraph:

Suitable sources of nucleic acids encoding CD44 polypeptide include for example the human CD44 nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. LO5407 and CAA40133, respectively. Other sources include human CD44 nucleic acid and protein sequences are shown in GenBank® Accession No. U35632 and P16079, respectively, and are incorporated herein by reference in their entirety. Suitable sources of nucleic acids encoding glycosyltransferase polypeptide include for example the human glycosyltransferase nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. AJ276689 and CAB81779, respectively. Suitable sources of nucleic acids encoding glycosidase polypeptide include for example the human glycosidase nucleic acid (and the encoded protein sequences) available as GenBank® Accession Nos. AJ278964 and CAC08178, respectively. The use of other CD44, glycosyltransferase, or glycosidase polypeptides and nucleic acids know in the art are also within the scope of the invention.

Please replace the paragraph beginning at page 65, line 4 with the following amended paragraph:

Applicant: Robert Sackstein Attorney's Docket No.: 10286-014001 / BWH-729

Serial No. : 10/042,421
Filed : October 18, 2001

Page : 4 of 22

cccaccgtggcccagtaccgcttct-3' (SEQ ID NO:4) and anti-sense 5'-ctgacctctgtgcccagcctcccgt-3' (SEQ ID NO:5) and thermal cycling conditions [RT at 52°C for 45 minutes, 1 cycle at 94°C for 2 minutes, 30 cycles at 94°C for 30 seconds, 60°C for 45 seconds and 72°C for 1 minute, and 1 cycle at 68°C for 7 minutes] were used. Using identical RT and thermal cycling conditions, a 0.50kb cDNA fragment of FucTIV was generated from sense 5'-cgggtgtgccaggctgtacagagg-3'(SEQ ID NO:6) and anti-sense 5'-tcgggaacagttgtgtatgagatt-3' (SEQ ID NO:7) primers (GenBank®, Accn#M58597).